The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Open accessAbstract
To convert the values for low-density lipoprotein (LDL) cholesterol to millimoles per liter, multiply by 0.02586.† Included in this category is the number of patients who underwent randomization and received at least one dose of a study drug.‡ Patients who were enrolled in phase 2 parent trials and who agreed to participate in the extension study were enrolled in OSLER-1.§ Patients who were enrolled in phase 3 parent trials and who agreed to participate in the extension study were enrolled in OSLER-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“with one agent showing benefit only among patients who had a baseline LDL cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter). 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both our trial and the SPIRE trial showed a more prominent absolute reduction in the risk of cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 100 mg or more per deciliter. 12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, there were little more than 100 events in these studies combined.”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
From Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (2018) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, exploratory data from longer-term follow-up in phase 2 and phase 3 trials of PCSK9 inhibitors showed significant reductions in cardiovascular outcomes.9,10”
From Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (2017) · cites this paper as [9]
In the citing paper
“No major effect on HDL-C has been reported, while TGs may increase in some predisposed patients [274].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“At the top daily dose of 24 g of cholestyramine, 20 g of colestipol, or 4.5 g of colesevelam, a reduction in LDL-C of 18-25% has been observed.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [274]
In the citing paper
“Proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibitors and nicotinic acid reduce Lp(a) by ≏ 30%. 115-117”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men. 115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Results in studies with PCSK9 inhibitors that included post-ACS/very high-risk patients were promising 115,116 and definitive outcome studies are awaited.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50e70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Recent data with PCSK9 inhibitors indicate a similar efficacy in reducing LDL-C in women vs. men.115,116”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [116]
In the citing paper
“Combination therapy using statin and ezetimibe prevents ASCVD incidence in patients with ACS. (Evidence level 1+, recommendation level: B).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“The IMPROVE-IT study636) which enrolled ACS subjects (secondary prevention) with controlled LDL-C levels (50–100 mg/dL) under simvastatin treatment, revealed a significantly lower ASCVD incidence in the group for which ezetimibe was added on to simvastatin treatment.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“Regarding the LDL-C management target, the IMPROVE-IT636) study revealed that lowering the LDL-C level to 53.6 mg/dL using statin–ezetimibe combination therapy suppressed cardiovascular events by 6.4% more than the group that had their LDL-C level controlled at 69.5 mg/dL with statins only.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [636]
In the citing paper
“(10,11).These agents dramatically reduce LDL-C levels over and above statin therapy, with favorable short-term outcomes data up to 18 months (11,12).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Self-citationEffects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Sorted by citations
Items 701–800 of 1,004
Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention
Moustafa, B., & Testai, F. D. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.106057 · Cited by 15
Approach to patients with elevated low-density lipoprotein cholesterol levels
Feingold, K. R., & Chait, A. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101658 · Cited by 18
Huang, C., Zhang, Y., Su, J., Guan, X., Chen, S., Xu, X., Deng, X., Zhang, L., & Huang, J. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s434908 · Cited by 15
Robinson, J. G., & Ray, K. K. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.306887 · Cited by 15
Self-citationMonoclonal Antibodies for the Treatment of Hypercholesterolemia: Targeting PCSK9
Alkindi, M., Siminovitch, K. A., Gupta, M., & Genest, J. J. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.04.013 · Cited by 15
The Application of the LDL Principle
Schade, D. S., Cavanaugh, B., Ramo, B. W., & Eaton, R. P. (2016) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2016.65012 · Cited by 15
Earnshaw, S., McDade, C. L., Chu, Y., Fleige, L. E., & Sievenpiper, J. L. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.02.012 · Cited by 15
Adhyaru, B. B., & Jacobson, T. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0666-x · Cited by 17
Alter, D. A., Tu, J. V., Koh, M., Jackevicius, C. A., Austin, P. C., Rezai, M. R., Bhatia, R. S., Johnston, S., Udell, J. A., & Ko, D. T. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007535 · Cited by 15
Elamin, A., Grafton‐Clarke, C., Chen, K. W., Obafemi, T., Luvai, A., Katira, R., & Davis, G. K. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2018-136171 · Cited by 15
Non–High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History
Levinson, S. S. (2019) · Laboratory Medicine · doi:10.1093/labmed/lmz032 · Cited by 15
An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity
Moșteoru, S., Gaiță, D. I., & Banach, M. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1828343 · Cited by 15
Daviglus, M. L., Ferdinand, K. C., López, J. A. G., Wu, Y., Monsalvo, M. L., & Rodríguez, C. J. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016839 · Cited by 15
Waldmann, E., Li-ya, W., Busygina, K., Altenhofer, J., Henze, K., Folwaczny, A., & Parhofer, K. G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265838 · Cited by 15
Marchis, G. M. D., Dittrich, T. D., Malik, R., Zietz, A. V., Kriemler, L. F., Ference, B. A., Dichgans, M., & Georgakis, M. K. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.09.007 · Cited by 14
Regression of coronary atheroma with statin therapy
Elshazly, M. B., Stegman, B., & Puri, R. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000234 · Cited by 15
Wang, Y., Wang, J., & Wang, S. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0270-7 · Cited by 16
Obeid, S. N., Frangieh, A. H., Räber, L., Yousif, N., Gilhofer, T. S., Yamaji, K., Jaguszewski, M. J., Aghlmandi, S., Adams, J., Bockhorn, Y., et al. (2018) · Cardiology Research and Practice · doi:10.1155/2018/9762176 · Cited by 15
Cho, K. H., & Hong, Y. J. (2020) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2020.140 · Cited by 16
Klaus, G., Taylan, C., Büscher, R., Schmitt, C. P., Pape, L., Oh, J. S., Driemeyer, J., Galiano, M., König, J. C., Schürfeld, C., et al. (2018) · Pediatric Nephrology · doi:10.1007/s00467-018-3906-6 · Cited by 14
Moore, K. J., & Goldberg, I. J. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306756 · Cited by 15
Human genetic insights into lipoproteins and risk of cardiometabolic disease
Stitziel, N. O. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000389 · Cited by 14
Luo, Y., Yuan, L., Liu, Z., Dong, W., Huang, L., Liao, A., Xie, Y., Liu, R., Lan, W., Cai, Y., et al. (2024) · Neurochemical Research · doi:10.1007/s11064-024-04272-z · Cited by 14
Kołodziejczak, M. M., & Navarese, E. P. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.011 · Cited by 14
Liang, D., Chang, L., Tu, Y., Li, Z., & Zhang, M. (2022) · Medicine · doi:10.1097/md.0000000000031199 · Cited by 14
Preclinical toxicity assessment of a peptide-based antiPCSK9 vaccine in healthy mice
Momtazi‐Borojeni, A. A., Banach, M., Tabatabaei, S. A., & Sahebkar, A. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114170 · Cited by 15
Mormone, A., Tortorella, G., Esposito, F., Caturano, A., Marrone, A., Cozzolino, D., Galiero, R., Marfella, R., Sasso, F. C., & Rinaldi, L. (2024) · Biomedicines · doi:10.3390/biomedicines12020432 · Cited by 17
Robinson, J. G., Heistad, D. D., & Fox, K. A. A. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.10.023 · Cited by 15
Self-citationAdvances in treatment of dyslipidaemia
Grundy, S. M. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.208 · Cited by 14
Boffa, M. B. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0622-1 · Cited by 15
Hirayama, A., Yamashita, S., Inomata, H., Kassahun, H., Cyrille, M., Ruzza, A., Yoshida, M., Kiyosue, A., Ma, Y., & Teramoto, T. (2017) · Circulation Journal · doi:10.1253/circj.cj-16-1016 · Cited by 14
Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
Dixon, D. L., Buckley, L. F., Trankle, C. R., Kadariya, D., & Abbate, A. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s114091 · Cited by 12
Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
Ciccarelli, G., D’Elia, S., Paulis, M. D., Golino, P., & Cimmino, G. (2018) · Diseases · doi:10.3390/diseases6010022 · Cited by 14
Statin intolerance and new lipid-lowering treatments
Mesi, O., Lin, C., Ahmed, H. M., & Cho, L. S. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20165 · Cited by 15
Berberine: Ins and outs of a nature-made PCSK9 inhibitor
Ataei, S., Kesharwani, P., & Sahebkar, A. (2022) · EXCLI journal · doi:10.17179/excli2022-5234 · Cited by 14
PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
Alannan, M., Seidah, N. G., & Merched, A. J. (2022) · Cells · doi:10.3390/cells11244132 · Cited by 17
Scherer, N., Dings, C., Böhm, M., Laufs, U., & Lehr, T. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.866 · Cited by 15
Sawano, M., Kohsaka, S., Abe, T., Inohara, T., Maekawa, Y., Ueda, I., Sueyoshi, K., Suzuki, M., Noma, S., Numasawa, Y., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182687 · Cited by 14
Evolocumab: Considerations for the Management of Hyperlipidemia
Wiggins, B. S., Senfield, J., Kassahun, H., Lira, A., & Somaratne, R. M. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0720-3 · Cited by 14
Self-citationPCSK9 inhibitors: a non-statin cholesterol-lowering treatment option
Pokrywka, G. S. (2018) · Postgraduate Medicine · doi:10.1080/00325481.2018.1436843 · Cited by 13
Fleck, L. M. (2016) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180115000705 · Cited by 14
Statins do not increase Markers of Cerebral Angiopathies in patients with Cardioembolic Stroke
Martí‐Fábregas, J., Medrano-Martorell, S., Merino, E., Prats‐Sánchez, L., Marín, R., Delgado‐Mederos, R., Camps‐Renom, P., Domeño, A. M., Gómez-Choco, M. J., Lara, L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-20055-3 · Cited by 14
Alkhalil, M. (2018) · Current Drug Metabolism · doi:10.2174/1389200219666180816141827 · Cited by 14
Petrov, I. S., Dumitrescu, A., Šnejdrlová, M., Zafrir, B., Wożakowska−Kapłon, B., Fábryová, Ľ., Pintarić, H., Bridges, I. M., & Petkova, R. T. (2019) · Advances in Therapy · doi:10.1007/s12325-019-0879-1 · Cited by 14
Hovland, A., Retterstøl, K., Mollnes, T. E., Halvorsen, B. L., Aukrust, P., & Lappegård, K. T. (2020) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2020.1775878 · Cited by 15
Song, K. H., Kim, Y. H., Im, A., & Kim, Y. H. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2017.4069 · Cited by 13
Akyol, Ö., Chiang, H., Burns, A. R., Yang, C.-Y., Woodside, D. G., Sawamura, T., Sánchez‐Quesada, J. L., Gotto, A. M., & Chen, C. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1649759 · Cited by 14
Drug Discovery for Coronary Artery Disease
Wan, Q., Qian, S., Yonghu, H., Zhang, Y., Peng, Z., Li, Q., Shu, B., Zhu, L., & Wang, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-2517-9_8 · Cited by 13
Zhang, Y., Zhang, Y., Zhang, B., Chen, Z., Wei, Y., Chen, P., Chang, C. C., Liu, G., Chen, K., Ding, J., et al. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.04.010 · Cited by 13
Novel Biomarkers for Atherosclerotic Disease: Advances in Cardiovascular Risk Assessment
Jigoranu, A. R., Roca, M., Costache, A. D., Mitu, O., Oancea, A. F., Miftode, R.-Ş., Haba, M. Ș. C., Botnariu, G., Maștaleru, A., Gavril, R. S., et al. (2023) · Life · doi:10.3390/life13081639 · Cited by 17
Atia, A., Aboeldahab, H. A., Wageeh, A., Elneny, M., Elmallahy, M., Elawfi, B., Aboelkhier, M. M., Elrosasy, A., Abdelwahab, M. M., Sayed, S., et al. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00621-5 · Cited by 13
Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis
Moustafa, B., Oparowski, D., Testai, S., Guman, I., & Trifan, G. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.107633 · Cited by 16
Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions
Mitsis, A., Myrianthefs, M. M., Sokratous, S., Karmioti, G., Kyriakou, M., Drakomathioulakis, M., Tzikas, S., Kadoglou, N. P. E., Karagiannidis, E., Nasoufidou, A., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12081670 · Cited by 15
Mendelian Randomization Studies in Atherosclerotic Cardiovascular Diseases
Ko, D. S., & Kim, Y. H. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.3.280 · Cited by 13
The year in cardiology 2015: prevention
Chapman, M. J., Blankenberg, S., & Landmesser, U. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv721 · Cited by 13
Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk
Farnier, M. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0743-8 · Cited by 14
Hipercolesterolemia familiar: artículo de revisión
Merchán, A., Ruiz, Á. J., Campo, R., Prada, C. E., Toro, J. M., Sánchez, R., Gómez‐Mesa, J. E., Jaramillo, N. I., Molina, D. I., Vargas‐Uricoechea, H., et al. (2016) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2016.05.002 · Cited by 18
Farnier, M. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000356 · Cited by 13
Lipoprotein(a)-apheresis in the light of new drug developments
Vogt, A. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.025 · Cited by 13
Descamps, O. S., Fraass, U., Dent, R. E., März, W., & Gouni‐Berthold, I. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12979 · Cited by 12
Brown, J. D., Sheer, R., Pasquale, M. K., Sudharshan, L., Axelsen, K. J., Subedi, P., Wiederkehr, D., Brownfield, F., & Kamal‐Bahl, S. J. (2017) · Value in Health · doi:10.1016/j.jval.2017.07.009 · Cited by 13
PCSK9 inhibition 2018: riding a new wave of coronary prevention
Ward, N. C., Page, M. M., & Watts, G. F. (2019) · Clinical Science · doi:10.1042/cs20171300 · Cited by 13
Ruge, T., Carlsson, A. C., Kjøller, E., Hilden, J., Kolmos, H. J., Sajadieh, A., Kastrup, J., Jensen, G. B., Larsson, A. O., Nowak, C., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.02.031 · Cited by 13
Akin, A. C., Barrila, M. T., Brandt, T. A., Brennan, J., Henegar, K. E., Hoagland, S., Kumar, R., Magano, J., McInturff, E. L., Nematalla, A. S., et al. (2019) · Organic Process Research & Development · doi:10.1021/acs.oprd.9b00104 · Cited by 13
Glicksberg, B. S., Amadori, L., Akers, N. K., Sukhavasi, K., Franzén, O., Li, L., Belbin, G. M., Akers, K. L., Shameer, K., Badgeley, M. A., et al. (2019) · BMC Medical Genomics · doi:10.1186/s12920-019-0542-3 · Cited by 15
Parikh, V. N. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.002964 · Cited by 12
Gouverneur, A., Sanchez-Peña, P., Veyrac, G., Salem, J., Bégaud, B., & Bezin, J. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07242-7 · Cited by 14
PCSK9 Inhibition in Atherosclerotic Cardiovascular Disease
Delialis, D., Dimopoulou, M., Papaioannou, M., Kotsira, G., Maneta, E., Mavraganis, G., Loutos, C., Georgiopoulos, G. A., & Stamatelopoulos, K. S. (2023) · Current Pharmaceutical Design · doi:10.2174/1381612829666230412105238 · Cited by 13
Seijas‐Amigo, J., Mauriz-Montero, M. J., Suárez‐Artime, P., Gayoso-Rey, M., Estany-Gestal, A., Casas-Martínez, A., González-Freire, L., Rodríguez-Vázquez, A., Pérez-Rodríguez, N. D., Villaverde-Piñeiro, L., et al. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00604-6 · Cited by 13
Evolocumab in the treatment of dyslipidemia: pre-clinical and clinical pharmacology
Page, M. M., & Watts, G. F. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1073712 · Cited by 13
Taylan, C., Schlune, A., Meißner, T., Ažukaitis, K., ten Cate, F. E. A. U., & Weber, L. T. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.08.006 · Cited by 13
Li, S., Zhao, X., Zhang, Y., Zhu, C., Guo, Y., Wu, N., Xu, R., Qing, P., Gao, Y., Sun, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12471 · Cited by 13
Replication and fine-mapping of genetic predictors of lipid traits in African–Americans
Feng, Q., Wei, W., Levinson, R. T., Mosley, J. D., & Stein, C. M. (2017) · Journal of Human Genetics · doi:10.1038/jhg.2017.55 · Cited by 13
Wang, E. Q., Plotka, A., Salageanu, J., Sattler, C., & Yunis, C. (2017) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12278 · Cited by 13
Implementation of a New Clinic-Based, Pharmacist-Managed PCSK9 Inhibitor Consultation Service
Atanda, A., Shapiro, N. L., Stubbings, J., & Groo, V. L. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.9.918 · Cited by 13
Biologics and Cardiovascular Disease
Taunay, J. V., Albelda, M. T., Frias, J. C., & Lipinski, M. J. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000595 · Cited by 14
Packard, C. J. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1003-x · Cited by 13
Amput, P., McSweeney, C., Palee, S., Phrommintikul, A., Chattipakorn, S. C., & Chattipakorn, N. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.138 · Cited by 13
Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase
Marini, I., Moschini, R., CORSO, A. D., & Mura, U. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4474-z · Cited by 13
Effect of Low Cholesterol on Steroid Hormones and Vitamin E Levels
Qamar, A., & Bhatt, D. L. (2015) · Circulation Research · doi:10.1161/circresaha.115.307345 · Cited by 13
Are the PCSK9 inhibitors the panacea of atherosclerosis treatment?
Stein, E. A., & Turner, T. A. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1348231 · Cited by 13
Self-citationPCSK9 Inhibitors for Homozygous Familial Hypercholesterolemia
Thompson, G. R. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.033 · Cited by 13
Recent advances in the management of transient ischemic attacks
Ortiz-Garcia, J., Gomez, C. R., Schneck, M. J., & Biller, J. (2022) · Faculty Reviews · doi:10.12703/r/11-19 · Cited by 14
Ou, Z., Yu, Z., Liang, B., Zhao, L., Li, J., Pang, X., Liu, Q., Xu, C., Dong, S., Sun, X., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.939791 · Cited by 12
PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations
Holmes, M. V., Kartsonaki, C., Boxall, R., Lin, K., Reeve, N. F., Yu, C., Lv, J., Bennett, D., Hill, M., Yang, L., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae009 · Cited by 13
Papantoniou, E., Arvanitakis, K., Markakis, K., Papadakos, S. P., Tsachouridou, Ο., Popovic, D. S., Koufakis, T., Germanidis, G. S., & Kotsa, K. (2024) · Life · doi:10.3390/life14040449 · Cited by 14
Rosenson, R. S., & Köenig, W. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6642-9 · Cited by 12
The Crisis of Vascular Disease and the Journey to Vascular Health
Creager, M. A. (2016) · Circulation · doi:10.1161/cir.0000000000000434 · Cited by 12
Turgeon, R. D., Anderson, T. J., Grégoire, J., & Pearson, G. J. (2017) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163517713031 · Cited by 3
Wan, H. I., Gumbiner, B., Joh, T., Riel, T., Udata, C., Forgues, P., & Garzone, P. D. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.09.009 · Cited by 12
Is There a Need to Revise Goals in the Management of Dyslipidemias?
Sinning, D., & Landmesser, U. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1128-6 · Cited by 12
The genetic counselor's role in management of patients with dyslipidemia
Brown, E. E. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000732 · Cited by 12
Colivicchi, F., Fusco, S. A. D., Arca, M., Leggio, M., Caldarola, P., Murrone, A., Valente, S., Urbinati, S., Roncon, L., Amodeo, V., et al. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001175 · Cited by 13
Impact of PCSK9 Immunization on Glycemic Indices in Diabetic Rats
Momtazi‐Borojeni, A. A., Jaafari, M. R., Abdollahi, E., Banach, M., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/4757170 · Cited by 13
PCSK9 Inhibition-Based Therapeutic Approaches: An Immunotherapy Perspective
Momtazi‐Borojeni, A. A., Pirro, M., Xu, S., & Sahebkar, A. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211027125245 · Cited by 12
Yang, S., Shen, W., Zhang, H., Wang, C., Yang, P., & Wu, Q. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07338-8 · Cited by 13
Senftleber, N. K., Andersen, M. K., Jørsboe, E., Stæger, F. F., Nøhr, A. K., Garcia‐Erill, G., Meisner, J., Santander, C. G., Balboa, R. F., Gilly, A., et al. (2023) · European Journal of Human Genetics · doi:10.1038/s41431-023-01485-8 · Cited by 12
Doggrell, S. A., & Lynch, K. A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1093109 · Cited by 12
Novel risk factors for acute coronary syndromes and emerging therapies
Tong, D. C., Wilson, A., & Layland, J. J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.148 · Cited by 12
Lappegård, K. T., Enebakk, T., Thunhaug, H., Ludviksen, J. K., Mollnes, T. E., & Hovland, A. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.09.001 · Cited by 12
Metadata
- Authors
- Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., Scott, R., Koren, M. J., & Stein, E. A.
- Affiliations
- University of Iowa (US)
- Harvard University (US)
- University of the Witwatersrand (ZA)
- University of Cape Town (ZA)
- Houston Methodist (US)
- Amgen (United States) (US)
- Jacksonville Center for Clinical Research (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1500-1509
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4238580056
- Semantic Scholar
- 3a2aa2d61647c779adc7c8fa42c75fb373940128
- Cited by
- 1,509
- References
- 26
- Citations by year
- 2026: 44 · 2025: 54 · 2024: 71 · 2023: 73 · 2022: 88 · 2021: 91 · 2020: 104 · 2019: 148 · 2018: 152 · 2017: 261 · 2016: 277 · 2015: 141
- FWCI
- 279.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- evolocumab, PCSK9 inhibitors, LDL cholesterol lowering, cardiovascular events, lipid-lowering therapy, drug efficacy, drug safety
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
